Log In
Print
BCIQ
Print
Print this Print this
 

Edarbyclor, Azilsartan medoxomil/chlorthalidone

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionFixed-dose combination of azilsartan medoxomil, an angiotensin II type 1 (AT1) receptor blocker, and chlorthalidone, a long-acting oral thiazide-like diuretic
Molecular Target Angiotensin II type 1 (AT1) receptor (AGTR1)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat hypertension
Regulatory Designation
Partner Arbor Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today